<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775697</url>
  </required_header>
  <id_info>
    <org_study_id>AABB1948</org_study_id>
    <nct_id>NCT00775697</nct_id>
  </id_info>
  <brief_title>Montelukast in Children With Wheezing</brief_title>
  <official_title>Montelukast Effects on Pulmonary Function in Children With Wheezing Aged Less Than 2 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study children with recurrent wheezing (&gt;/= 2 episodes in the last 6 months)and aged
      less than 2 years will be enrolled as outpatients. They will undergo lung function evaluation
      by Rint and by assessment of the flow curves at baseline and after 4 weeks of treatment with
      Montelukast 4 mg/day. Symptom dairies will be filled by parents during the study period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients aged less than 2 years with recurrent wheezing. At visit 1 patients with symptoms
      will be enrolled and the study explained. They will return home with bronchodilator therapy.

      Within 1 week they will return for visit 2 to start a run-in period with bronchodilators prn
      and they will fill dairies with symptoms and drug use. Skin prick test will be evaluated at
      that time.

      At visit 3 after 1 week of the run-in period they will start therapy with Montelukast 4 mg
      for 4 weeks, using bronchodilators prn and filling diaries.

      The final visit will be after four weeks with re-evaluation of the lung function
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung function test (flow and resistance)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchodilator use Dairy symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Wheezing</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the single arm will receive montelukast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>the arm will be treated with Montelukast 4 mg die for 4 weeks</description>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>antileukotrienes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>montelukast 4 mg day for 4 weeks</description>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>antileukotrienes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 6-24 months

          -  Patients with recurrent wheezing (at least 2 episodes in the last 6 months)

          -  Patients with symptoms at enrollment

        Exclusion Criteria:

          -  Chronic respiratory diseases (cystic fibrosis, chronic lung disease) symptoms at visit
             1 that require hospital admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attilio L Boner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Pediatrica Universita' di Verona Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Boner Attilio</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>wheezing</keyword>
  <keyword>children</keyword>
  <keyword>montelukast</keyword>
  <keyword>bronchodilators</keyword>
  <keyword>lung function</keyword>
  <keyword>Rint</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Leukotriene Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

